読み込み中
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
前日終値
$17.59
+$0.42 · +2.45%
日中の時刻はETです。市場データは遅延する場合があります。
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
日中レンジ
現在 $17.59
52週レンジ
現在 $17.59
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
27
割高
センチメント
65
強気
リスク
57
やや高いリスク
モメンタム
29
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
日中レンジ
現在 $17.59
52週レンジ
現在 $17.59
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | 58.32万 USD | 133.77万 USD |
| 粗利益 | — | — | — | 58.32万 USD | 133.77万 USD |
| 研究開発 | 5.38億 USD | 1.32億 USD | 4.55億 USD | 4301.46万 USD | 6311.52万 USD |
| 販売・一般管理 | 5.57億 USD | 4834.53万 USD | 2374.08万 USD | 2212.23万 USD | 1745.96万 USD |
| 営業費用 | 10.94億 USD | 1.81億 USD | 4.78億 USD | 6021.67万 USD | 6506.97万 USD |
| 受取利息 | 1550.1万 USD | 1346.6万 USD | 1040.3万 USD | 151.3万 USD | — |
| 支払利息 | — | 868.6万 USD | 1646.1万 USD | 440.1万 USD | 20.83万 USD |
| 減価償却費と償却費 | 14.6万 USD | 8.9万 USD | 19.8万 USD | 126.3万 USD | 245.5万 USD |
| 営業利益 | −10.94億 USD | −1.81億 USD | −4.78億 USD | −5963.35万 USD | −6373.2万 USD |
| 純利益 | −10.8億 USD | −1.77億 USD | −4.82億 USD | −6517万 USD | −6551.85万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$29.33
上昇余地（66.74%）この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P Biotech ETFXBI6325.87万0.64%98.74億 USD0.35%$153.77+3.00%
Vanguard Morningstar Total Stock Market ETFVTI5060.97万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB3646.74万0.02%1853億 USD0.03%$289.48+0.64%
Vanguard Extended Market ETFVXF2459.88万0.03%954億 USD0.05%$235+0.80%
Vanguard Morningstar Small-Cap Value ETFVBR2317.06万0.03%682億 USD0.05%$234.43+0.22%
iShares Biotechnology ETFIBB2028.25万0.19%108.2億 USD0.44%$206.49+3.00%
iShares Russell Mid-Cap Growth ETFIWP1342.31万0.07%200.95億 USD0.23%$143.1+1.56%
iShares Russell Mid-Cap ETFIWR986.57万0.02%567.65億 USD0.18%$109.82+0.87%State Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap Value ETFVBRiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPiShares Russell Mid-Cap ETFIWRAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
